Recent advances in immunotherapy for the treatment of prostate cancer
/in Dendritic Cells, International Publications, Prostate CancerImmunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research
/in Dendritic Cells, International Publications, Prostate CancerImprovement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus.
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease VirusResults of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).
/in Dendritic Cells, International Publications, Prostate CancerMelanoma patients treated with dendritic cell vaccination, interleukin-2, and metronomic cyclophosphamide: Results from a phase II trial.
/in Dendritic Cells, International Publications, Malignant MelanomaA dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study.
/in Colorectal Cancer, Dendritic Cells, International PublicationsSurvival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.
/in Colorectal Cancer, Dendritic Cells, International PublicationsImmuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers
/in Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer